<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01070680</url>
  </required_header>
  <id_info>
    <org_study_id>a004c</org_study_id>
    <secondary_id>2009-014862-25</secondary_id>
    <nct_id>NCT01070680</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Versus Placebo in Endoscopic Retrograde Cholangiopancreatography (ERCP) Sedation</brief_title>
  <official_title>Dexmedetomidine vs Placebo in ERCP Sedation.A Randomized Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helsinki University Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helsinki University Central Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this pilot prospective non-commercial clinical trial the investigators will study the use
      of dexmedetomidine as an adjuvant to the patient-controlled propofol sedation in a
      placebo-controlled and randomized manner in patients with drug addiction during Endoscopic
      Retrograde Cholangiopancreatography (ERCP). Dexmedetomidine is a sedative medication used
      mostly in intensive care units,and is marketed under the brand name Precedex. Dexmedetomidine
      has sedative, analgesic, sympatholytic, and anxiolytic properties. It produces sedation
      without causing significant respiratory depression. Recent research has suggested
      dexmedetomidine to be effective in treatment of alcohol withdrawal signs. In previous studies
      dexmedetomidine was insufficient as an only sedative agent in ERCP and colonoscopy, but it
      has not been assessed for sedation in patients with chronic pancreatitis. The main objective
      of this trial is to evaluate if dexmedetomidine can reduce propofol and opioid consumption
      and facilitate the performance of ERCP in patients with chronic pancreatitis due to drug
      addiction.Secondary objectives of the trial are the stability of vital signs and safety,
      patients´ satisfaction plus recovery time from sedation.

      50 elective ERCP patients with chronic pancreatitis after written informed consent and
      randomisation will be recruited to the study. Exclusion criteria are:allergy to propofol,
      opioid or dexmedetomidine, ASA class greater than 3. All the patients will receive
      patient-controlled propofol sedation. In dexmedetomidine group dexmedetomidine infusion will
      be started before sedation beginning and in placebo group placebo-solution (NaCl0,9%) will be
      administered in the similar manner.Standard monitoring for vital signs will be applied,also
      sedation degrees will be evaluated with sedation scores. At the end of procedure total amount
      of propofol and opioid will be calculated,patients and endoscopists satisfaction and the
      difficulty of ERCP will be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sedation degree</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>propofol consumption</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>endoscopist´s and patient´s satisfaction</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>vital signs:blood pressure, oxygen saturation, heart rate, breathing rate</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Pancreatitis</condition>
  <arm_group>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sedative medicine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sodium chloride 0,9%</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Precedex</intervention_name>
    <description>mkg/ml,continuous infusion at rate 0.7 µg/kg/h</description>
    <arm_group_label>dexmedetomidine</arm_group_label>
    <other_name>dexmedetomidine hydrochloride injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium chlorid 0,9%</intervention_name>
    <description>continuous intravenous infusion</description>
    <arm_group_label>sodium chloride 0,9%</arm_group_label>
    <other_name>NaCl 0,9%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective ERCP-patients with chronic alcohol pancreatitis

        Exclusion Criteria:

          -  Allergy to the dexmedetomidine, propofol or any opioid, ASA(American Society of
             Anaesthesiology)class grater when 3
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxim Mazanikov, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Anaesthesiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marianne Udd, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Outi Lindström, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leena Kylänpää, Docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jorma Halttunen, Docent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martti Färkkilä, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital,Department of Gastroenterology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Reino Pöyhiä, Docent</last_name>
    <role>Study Director</role>
    <affiliation>Helsinki University Central Hospital,Department of Anaesthesiology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Harri Mustonen, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Gastrointestinal and General Surgery, Helsinki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Helsinki University Central Hospital,Meilahti hospital,Endoscopy unit</name>
      <address>
        <city>Helsinki</city>
        <state>Uusimaa</state>
        <zip>00029</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2010</study_first_submitted>
  <study_first_submitted_qc>February 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2010</study_first_posted>
  <last_update_submitted>July 13, 2012</last_update_submitted>
  <last_update_submitted_qc>July 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helsinki University Central Hospital</investigator_affiliation>
    <investigator_full_name>Maxim Mazanikov</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>ERCP</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>propofol</keyword>
  <keyword>patient-controlled sedation</keyword>
  <keyword>Chronic Alcoholic pancreatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

